Letter to the Editor: Re: “Comparison of Treatment Strategies for Patients With Clinical Stage T1–3/N2 Lung Cancer”

Authors: Junmiao Wen MD1 and Donglai Chen MD2
View More View Less
  • 1 Fudan University Shanghai Cancer Center, Shanghai, China; and
  • | 2 Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Restricted access
  • 1.

    Cheng YF, Hung W, Chen H, et al. Comparison of treatment strategies for patients with clinical stage T1–3/N2 lung cancer. J Natl Compr Canc Netw 2020;18:143150.

  • 2.

    Ruhl J, Adamo M, Dickie L. (February 2016). SEER Program Coding and Staging Manual 2016: Section V. National Cancer Institute, Bethesda, MD 208509765.

    • Search Google Scholar
    • Export Citation
  • 3.

    National Cancer Institute. Surveillance, Epidemiology, and End Results. Radiation/Chemotherapy Databases (1975–2016). Accessed July 6, 2020. Available at: https://seer.cancer.gov/data/treatment.html

    • Search Google Scholar
    • Export Citation
  • 4.

    Lim YJ, Song C, Kim JS. Improved survival with postoperative radiotherapy in thymic carcinoma: a propensity-matched analysis of Surveillance, Epidemiology, and End Results (SEER) database. Lung Cancer 2017;108:161167.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Sullivan J, Weksler B. Neuroendocrine tumors of the thymus: analysis of factors affecting survival in 254 patients. Ann Thorac Surg 2017;103:935939.

  • 6.

    Noone AM, Lund JL, Mariotto A, et al. Comparison of SEER treatment data with Medicare claims. Med Care 2016;54:e5564.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 317 154 3
PDF Downloads 127 83 4
EPUB Downloads 0 0 0